Date: Monday, 9 September 2024
Time: 13:00-14:30
Location: Room Spadolini 7
In gastric cancer, HER2 was the first biomarker for guided therapy registered for clinical use. Considering the recent approvals of immune check-point blockade in gastroesophageal cancers, testing for mismatch repair deficiency (dMMR) and PD-L1 combined positive score (CPS) is becoming increasingly important.
If you have an interest on sharing valuable strategies as tips and tricks from these three key opinion leaders, as review some updates regarding testing requirements in gastric cancer, please join us.
Agilent will offer a lunch box during the symposium, and you will receive a digital certification of attendance.
This free educational event is offered by Medical Affairs at Agilent Technologies Inc. Your attendance is not conditional upon any
obligation for you to use, recommend, promote, or purchase Agilent products nor is it intended to influence you to do so.
PR7001-2710 | D0115931_1.00
Please fill out all details required.